The effect of PPAR-γ agonist on 18F-FDG uptake in tumor and macrophages and tumor cells

Nuclear Medicine and Biology

Volumn 36, Issue 4, 2009, Pages 427-433

  Kim, Se Lim ^a   Kim, Eun Mi ^a   Cheong, Su Jin ^a   Lee, Chang Moon ^a   Kim, Dong Wook ^a   Jeong, Hwan Jeong ^a   Lim, Seok Tae ^a   Sohn, Myung Hee ^a   Yim, Chang Yeol ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

18F FDG; Macrophages; PPAR ; Tumor cells

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; HEXOKINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DIMETHYL SULFOXIDE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HEXOKINASE; HUMANS; INFLAMMATION; MACROPHAGES; MICE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PPAR GAMMA; THIAZOLIDINEDIONES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67349253532     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.010     Document Type: Article

References (37)

1. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 240 (1988) 889-895
2. Spiegelman B.M., and Flier J.S. Adipogenesis and obesity: rounding out the big picture. Cell 87 (1996) 377-389
3. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
4. Berger J.P., Petro A.E., Macnaul K.L., Kelly L.J., Zhang B.B., Richards K., et al. Distinct properties and advantages of a novel peroxisome proliferator-activated receptor [gamma] selective modulator. Mol Endocrinol 17 (2003) 662-676
5. Serhan C.N. Inflammation. Signaling the fat controller. Nature 384 (1996) 23-24
6. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137 (1996) 354-366
7. Chinetti G., Griglio S., Antonucci M., Torra I.P., Delerive P., Majd Z., et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273 (1998) 25573-25580
8. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49 (2000) 497-505
9. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., and Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164 (2000) 1364-1371
10. Faveeuw C., Fougeray S., Angeli V., Fontaine J., Chinetti G., Gosset P., et al. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 486 (2000) 261-266
11. Gosset P., Charbonnier A.S., Delerive P., Fontaine J., Staels B., Pestel J., et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 31 (2001) 2857-2865
12. Marx N., Sukhova G., Murphy C., Libby P., and Plutzky J. Macrophages in human atheroma contain PPAR-gamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPAR-gamma) expression and reduction of MMP-9 activity through PPAR-gamma activation in mononuclear phagocytes in vitro. Am J Pathol 153 (1998) 17-23
13. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists. PPAR-gamma co-association with transcription factor NFAT. J Biol Chem 275 (2000) 4541-4544
14. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferators activated receptor-γ is a negative regulator of macrophages activation. Nature 391 (1998) 79-82
15. Jiang C., Ting A.T., and Seed B. PPAR-γ Agonists inhibit the production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
16. Flier J.S., Mueckler M.M., Usher P., and Lodish H.F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235 (1987) 1492-1495
17. 18F]- fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr 13 (1989) 829-831
18. 18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr 14 (1990) 486-487
19. Lewis P.J., and Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 35 (1994) 1647-1649
20. Ichiya Y., Kuwabara Y., Sasaki M., Yoshida T., Akashi Y., Murayama S., et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med 10 (1996) 185-191
21. Hanson M.W., Glantz M.J., Hoffman J.M., Friedman A.H., Burger P.C., Schold S.C., et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 15 (1991) 796-801
22. Meyer M.A., Frey K.A., and Schwaiger M. Discordance between F-18 fluorodeoxyglucose uptake and contrast enhancement in a brain abscess. Clin Nucl Med 18 (1993) 682-684
23. Sugawara Y., Braun D.K., Kison P.V., Russo J.E., Zasadny K.R., and Wahl R.L. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med 25 (1998) 1238-1243
24. 125I-HSA. Eur J Nucl Med 26 (1999) 333-341
25. Yamada S., Kubota K., Kubota R., Ido T., and Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 36 (1995) 1301-1306
26. Toffoli G., Claudia C., Russo A., Gallo A., Bagnoli M., and Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74 (1997) 193-197
27. Mochizuki T., Tsukamoto E., Kuge Y., Kanegae K., Zhao S., Hikosaka K., et al. FDG Uptake and glucose transporter subtype expressions in experimental tumor and inflammation model. J Nucl Med 42 (2001) 1551-1555
28. Mellanen P., Minn H., Grénman R., and Härkönen P. Expression of glucose transporters in head-and-neck tumors. Int J Cancer 56 (1994) 622-629
29. Marom E.M., Aloia T.A., Moore M.B., Hara M., Herndon II J.E., Harpole Jr. D.H., et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 33 (2001) 99-107
30. Higashi T., Tamaki N., Honda T., Torizuka T., Kimura T., Inokuma T., et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 38 (1997) 1337-1344
31. Higashi T., Tamaki N., Torizuka T., Nakamoto Y., Sakahara H., Kimura T., et al. FDG Uptake, Glut-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 39 (1998) 1727-1735
32. 18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med 27 (2000) 1778-1785
33. 18F-2-fluoro-2-deoxy-d-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 51 (2006) 2198-2205
34. 18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 33 (2006) 683-691
35. Tian M., Zhang H., Nakasone Y., Mogi K., and Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 31 (2004) 5-12
36. Rasey J.S., Grierson J.R., Wiens L.W., Kolb P.D., and Schwartz J.L. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43 (2002) 1210-1217
37. 18F-FDG. J Nucl Med 44 (2003) 1426-1431